• In August 2026, Kenvue's Zyrtec brand launched Zyrtec Allergen Shield Spray, a drug-free nasal mist that forms a gel barrier in the nose within minutes to help block common airborne allergens like pollen, pet dander, and dust for up to six hours in adults and children aged 12 and older.

• This first-of-its-kind, HPMC-based spray expands Zyrtec's toolkit toward proactive allergen defense, signaling Kenvue's push into drug-free, preventative allergy solutions.

• We'll now examine how this new drug-free, barrier-forming allergy spray could shape Kenvue's broader investment narrative around innovation and growth.

Find 50 companies with promising cash flow potential yet trading below their fair value .

Kenvue Investment Narrative Recap

To own Kenvue, you need to believe its consumer health brands can keep earning trust while the company simplifies operations and adapts to shifting buying habits. Zyrtec Allergen Shield Spray fits the push toward preventative, drug free solutions, but on its own it does not materially change the near term focus on executing the Kimberly Clark merger or the risk that Kenvue's innovation pace lags changing consumer preferences.

The Zyrtec Allergen Shield launch sits squarely in Kenvue's effort to accelerate consumer centric innovation in preventative health, a key catalyst that could help refresh mature brands. This product arrives alongside recent Q2 2026 results that showed higher sales and earnings, giving investors fresh data as they weigh how much new launches can support growth while Kenvue continues to streamline its portfolio and ramp up e commerce.

However, investors should also be aware that Kenvue's slower shift toward e commerce and digital retail could...

Read the full narrative on Kenvue (it's free!)

Kenvue's narrative projects $16.7 billion revenue and $2.3 billion earnings by 2029. This requires 2.9% yearly revenue growth and about a $0.7 billion earnings increase from $1.6 billion today.

Uncover how Kenvue's forecasts yield a $19.50 fair value , a 3% upside to its current price.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community span roughly US$19.50 to US$29.76, showing how far apart individual views on Kenvue sit. As you consider these opinions, weigh them against the company's push into preventative, drug free allergy solutions and what that might mean for Kenvue's ability to refresh legacy brands and support future performance.

Explore 3 other fair value estimates on Kenvue - why the stock might be worth as much as 57% more than the current price!